Results 91 to 100 of about 61,152 (267)

Glucose-dependent insulinotropic polypeptide (GIP) and GIP receptor (GIPR) genes: An association analysis of polymorphisms and bone in young and elderly women

Bone Reports, 2016
Introduction: The gastro-intestinal hormone glucose-dependent insulinotropic polypeptide (GIP) potentiates glucose-induced insulin secretion, with bone anabolic effects through GIP receptor (GIPR) in animal models.
Gaurav Garg, Fiona E. McGuigan, Jitender Kumar, Holger Luthman, Valeriya Lyssenko, Kristina Akesson   +5 more
doaj   +1 more source

Reduced‐Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate whether reduced‐frequency dosing of GLP1 receptor agonists maintains weight loss, body composition, and metabolic syndrome improvements following successful initial treatment with standard weekly therapy. Methods This retrospective case series included 30 adults who achieved weight plateau while on weekly
Michelle Wong, Ash Wu, Pawanjot K. Garhe, Mitch Biermann   +3 more
wiley   +1 more source

Crystallization and 1.6 Å resolution crystal structure of an acylated GLP-1/GIP analogue peptide. [PDF]

Acta Crystallogr F Struct Biol Commun
The 1.6 Å resolution diffraction and subsequent structure solution of an acylated GLP‐1/GIP analogue lipopeptide is reported. This represents the first published data on the crystal structure of an unbound GLP‐1 and/or GIP analogue lipopeptide.With the meteoric rise in interest in GLP‐1 and GIP analogue peptides in recent years, there is a drive for ...
Mitchell HM, Nocek B, Guinn EJ, Heng JYY.   +3 more
europepmc   +2 more sources

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

Retatrutide Shows Multiple Metabolic Benefits in Diet‐Induced Obese MASH Mouse and Hamster Models

Obesity, EarlyView.
ABSTRACT Objective/Methods Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP‐1 receptor agonist retatrutide in diet‐induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
François Briand, Camille Le Cudennec, Estelle Grasset, Natalia Breyner, Claire Bigot, Pierre Dillard, Thierry Sulpice   +6 more
wiley   +1 more source

Gastrointestinal parasitic infections: Prevalence and risk factors in West Ismailia, Arab Republic of Egypt

Gut Pathogens
Background This study aimed to determine the prevalence of gastrointestinal parasites (GIP) in the rural community of West Ismailia and its associated risk factors. Human infection by GIP is natural and expected.
Shahira Abdelaziz Ali Ahmed, Samar Farag Mohamed, Heba Sayed El-Mahallawy, Annalisa Quattrocchi, Panagiotis Karanis   +4 more
doaj   +1 more source

Twenty‐Four Month Outcomes From a Real‐World Telehealth Obesity Treatment Clinic Using Obesity Medications

Obesity, EarlyView.
ABSTRACT Objective Antiobesity medications (AOMs) are indicated for long‐term use; however, evidence of their real‐world long‐term efficacy is limited. This study describes clinical outcomes from 18‐ and 24‐month use of AOMs in a telemedicine weight management clinic.
Kathleen R. Ruddiman, Young‐Rock Hong, Jamy Ard, Rebecca Jones, Adam Medcalf, Gary D. Foster, Jamil Alkhaddo, Michelle Cardel   +7 more
wiley   +1 more source

GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene

Journal of Lipid Research, 2010
GIP (glucose-dependent insulinotropic polypeptide) is a gastrointestinal hormone that regulates pancreatic islet function. Additionally, emerging evidence suggests an important physiological role for GIP in the regulation of adipocyte metabolism.
Su-Jin Kim, Cuilan Nian, Christopher H.S. McIntosh   +2 more
doaj   +1 more source

Weight Loss With GLP‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective Two glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA‐approved for weight loss in adults with obesity without type 2 diabetes mellitus. This systematic review and network meta‐analysis aims to compare the efficacy of these agents against each other.
Michael Lim, Pooja Gokhale, Akwasi Akosah, Lorenzo Villa‐Zapata   +3 more
wiley   +1 more source

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source